Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ThisCART22

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Fundamenta Therap

Drug class:

CD22-targeted CAR-T immunotherapy, T lymphocyte replacement

Related drugs:

‹

anti-KRAS G12D mTCR PBL (0)

marrow infiltrating lymphocytes (0)

CAR-T19/CAR-T22 immunotherapy (1)

4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)

Anti-CD19/CD20/CD22 CAR T-Cells (0)

Anti-CD22 CAR-T Cells (0)

CAR-T CD19/CD20/CD22/CD30 (0)

CAR20.19.22 T (0)

CD19 and CD22 targeted prime CAR-T (0)

CD19-CD22 CAR-T (0)

CD19/CD22 CAR T-cells (0)

CD19/CD22 CAR-T cell therapy (0)

CD19/CD22 chimeric antigen receptor T cell (0)

CD19/CD22 dual-target CAR-T (0)

CD19x22 CAR T (0)

CD22-targeted CAR-T cell therapy (0)

CD22/CD19 CAR T (0)

MB-CAR-T19-22 (0)

SCRI-CAR19x22v2 (0)

SCRI-CAR22v2 (0)

Senl_H19x22P (0)

anti-CD19/CD22 CAR-T cells (0)

anti-CD22 CAR T (0)

anti-CD22 CAR-T cell therapy (0)

anti-CD22 CAR-T therapy (0)

anti-CD22-CAR (0)

autologous TriCAR T (0)

multi-CAR-T cell therapy (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

sequential different B cell antigen-targeted CAR T-cell therapy (0)

H3.3K27M TCR T cell therapy (0)

allodepleted T-cell immunotherapeutics (0)

anti-KRAS G12D mTCR PBL (0)

marrow infiltrating lymphocytes (0)

›

3years

Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma (clinicaltrials.gov)

P1, N=20, Recruiting, Fundamenta Therapeutics, Ltd.

3 years ago

Clinical • New P1 trial

|

CD22 (CD22 Molecule)

|

ThisCART22